Hodgkin Lymphoma
Conference Coverage
CAR T may have curative potential in Hodgkin lymphoma
NEW YORK – Early trials point to potential for CD30-specific CAR T-cell therapy.
News
Drug approved as part of frontline therapy for HL
The Japanese Ministry of Health, Labour and Welfare has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and...
Latest News
Brentuximab vedotin boosts elderly Hodgkin survival
Adding Bv to standard chemotherapy improved survival over historical rates.
News
Guidelines for proton therapy in mediastinal lymphomas
Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but the treatment should only be used in patients expected to...
News
Role of SES in childhood cancer survival disparities
Socioeconomic status (SES) may explain some racial/ethnic disparities in childhood cancer survival, according to new research. The study showed...
News
Auto-HSCT linked to higher AML, MDS risk
Patients undergoing autologous hematopoietic stem cell transplant (auto-HSCT) for lymphoma or myeloma have an increased risk of acute myeloid...
News
Frequent BCCs linked to blood cancers
New research suggests people who develop frequent cases of basal cell carcinoma (BCC) have an increased risk of leukemias, lymphomas, and other...
News
Adult CCSs report financial hardships
Health-related financial hardship is common among adult survivors of childhood cancer, according to a study published in the Journal of the...
News
Global burden of hematologic malignancies
Research has shown an increase in the global incidence of leukemia and non-Hodgkin lymphoma (NHL) in recent years. The Global Burden of Disease (...
From the Journals
Late mortality risk after childhood BMT is substantial, persistent
Patients who undergo blood or marrow transplant as children need “lifelong follow-up care.”
News
FDA approves biosimilar filgrastim
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (...